Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
about
CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected IndividualsThe role of DNA amplification technology in the diagnosis of infectious diseasesNormal physiology and HIV pathophysiology of human T-cell dynamicsThe lymph node in HIV pathogenesisA microchip CD4 counting method for HIV monitoring in resource-poor settings.CD4 measurements in patients with HIV: are they feasible for poor settings?Screening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa: A Cost-Effectiveness AnalysisInfectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventionsKinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infectionsSIVagm infection in wild African green monkeys from South Africa: epidemiology, natural history, and evolutionary considerationsSoluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitroAnti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replicationIllustration of a measure to combine viral suppression and viral rebound in studies of HIV therapyHIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmissionPhylogenetic approach reveals that virus genotype largely determines HIV set-point viral loadCost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisalScaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysisNational prevalence and trends of HIV transmitted drug resistance in MexicoWHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothersWhat will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysisNovel use of surveillance data to detect HIV-infected persons with sustained high viral load and durable virologic suppression in New York CityThe cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysisDiscordance in CD4+T-cell levels and viral loads with co-occurrence of elevated peripheral TNF-α and IL-4 in newly diagnosed HIV-TB co-infected casesBaseline CD4 cell counts of newly diagnosed HIV cases in China: 2006-2012HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHepatitis B vaccine antibody response and the risk of clinical AIDS or deathCost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in CambodiaDesigning and managing a flexible and dynamic biorepository system: a 15 year perspective from the CPCRA, ESPRIT, and INSIGHT clinical trial networksCD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytesInitiation of antiretroviral therapy.French HIV experts on early antiretroviral treatment for prevention: uncertainty and heterogeneity.Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral loadCD4 immunophenotyping in HIV infection.HIV-1 Disease Progression and Survival in an Adult Population in Zimbabwe: Is There an Effect of the Mannose Binding Lectin Deficiency?Performance of computer vision in vivo flow cytometry with low fluorescence contrast.Advances in developing HIV-1 viral load assays for resource-limited settingsPatient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability.Maximum likelihood inference for left-censored HIV RNA data.
P2860
Q19028101-4A00D266-EDFE-4520-8CD9-BB81E947A2E4Q24555005-E153CDE6-7E79-4539-82A5-647F6C3EF716Q24630194-F6AD5806-BAC6-4DF9-B521-2D5AE15EB0DCQ24644783-1444486F-624B-4C42-8A1C-5661040AD956Q24812883-E05F0B06-1D42-4CB6-A2E3-42531ABB91C1Q24812905-D4C8D4EA-9642-4116-BC25-768437814F94Q26779464-35B343B8-D87A-47E5-95EA-AA2441D57EADQ26823594-BA9554EE-31E4-41B6-9872-955742958541Q27333255-C78195BE-AEBE-4E45-8E58-93EB20FB6DB1Q27340281-093D4183-C949-4323-819B-24388BCFCAEDQ27690715-9BBCDDB0-AAC8-4629-B276-CACB5A97EB14Q28343837-BA7FD649-78EB-4AD9-9D87-F7122628181EQ28369925-13B149ED-BB65-410C-9148-C092483BDFCCQ28385909-18D6C9FF-42C0-4049-918C-5404BD542B91Q28473637-819EE5CB-4270-448B-973A-3043B400C6D9Q28475652-AE3F6FC7-FD33-4C87-9893-CECAA03A7AB2Q28476337-6A1E8AC1-C589-438D-94F2-6F77DEE5ABFDQ28476684-E7E6FF93-2BF7-4DB1-B662-CB7F45C4E85BQ28477977-80F6D0DD-5DB1-4214-BFD4-B26515EBEE96Q28478406-4D82ABAA-4ADB-44AB-917A-5132AFCC5B90Q28478769-45A5F21A-3E16-4AA3-A10A-E88D60B98B0EQ28479045-84D1F45D-EEBE-4DDA-A76C-0A058A5BF403Q28483035-284DB25A-D406-4DAB-86F3-CDFFF85B51A8Q28535056-C5FB1BFF-5E32-403C-8037-C08C6EB33645Q28539411-66F88623-1E02-4BD8-AEE0-7E5F0634D284Q28606620-6F759C08-31FE-490D-BB9F-E50646068D62Q28730976-5D517B21-16F4-476F-B0BA-9D256E02DC2FQ28748511-2EB1A1FC-BB1F-417A-9F51-3B0CA518DC3BQ28972361-E5CEF865-6CC0-474D-A9C7-775BB4F78C88Q29026902-8D66CAD4-2479-403C-B452-FFB61E17408CQ30209635-3F845E3F-92B5-4089-8AE3-338836EACF2CQ30222819-9054B639-2B1C-4182-8D52-E8FDE7DFFABBQ30336405-F5D59031-0219-4E13-9029-45BC67D47A61Q30363755-11A24A75-0084-4ED5-9A31-3C27D346A300Q30372724-7A28EF27-FB72-4E0B-B6DE-F299B374D2EAQ30378916-3366388E-E179-45EA-AD6D-0B9AA4971CB5Q30387440-434EAE93-0D9E-4F53-9A9E-F59A86EC0E6FQ30473238-F4CA7196-847C-44AC-A059-4CB095499475Q30528513-C2705A9A-ADDE-40D0-AA07-F70E8557575AQ30622213-A7F16707-CD63-4A42-887F-9D90D88764E7
P2860
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@ast
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@en
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@nl
type
label
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@ast
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@en
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@nl
prefLabel
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@ast
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@en
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@nl
P2093
P921
P1476
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
@en
P2093
Kingsley LA
Margolick JB
Mellors JW
Rinaldo CR Jr
P304
P356
10.7326/0003-4819-126-12-199706150-00003
P407
P577
1997-06-01T00:00:00Z